\-\ Texto\\:\\ \ \(0\)\
\-\ standard\\ treatment\\:\\ abvd\\ w\\/xrt\ \(0\)\
\-\ adriamycin\\ \\[doxorubicin\\]\\,\\ bleomycin\\,\\ vinblastine\\,\\ dacarbazine\ \(0\)\
\-\ prognosis\\ is\\ good\\,\\ especially\\ for\\ young\\ pts\\ with\\ early\\-stage\\ disease\\ 5\\ year\\ survival\\ rate\\ of\\ 90\\%\ \(0\)\
\-\ \\â\\€\\¢\\ anterior\\ \\(superior\\)\\ mediastinal\\ mass\\,\\ surrounding\\ the\\ great\\ vessels\\ and\\ aortic\\ arch\\.\ \(0\)\
\-\ nodular\\ sclerosing\\ hodgkin\\â\\€\\™s\\ lymphoma\ \(0\)\
\-\ mediastinal\\ mass\\:\ \(2\)\
\-\ \\â\\€\\¢\\ thymoma\\ \ \(0\)\
\-\ most\\ common\\ 1\\Â\\°\\ anterior\\ mediastinal\\ mass\\ \\(20\\%\\)\ \(0\)\
\-\ \\â\\€\\¢\\ lymphoma\ \(6\)\
\-\ \\â\\€\\¢\\ germ\\ cell\\ tumors\ \(1\)\
\-\ \\â\\€\\¢\\ mediastinal\\ cysts\ \(0\)\
\-\ \\â\\€\\¢\\ pericardial\\,\\ bronchogenic\\,\\ enteric\\,\\ thymic\ \(0\)\
\-\ \\â\\€\\¢\\ aneurysm\\ of\\ ascending\\ aorta\ \(0\)\
\-\ \\â\\€\\¢\\ thyroid\\/parathyroid\\ tissue\ \(0\)\
\-\ a\\ previously\\ healthy\\ 23\\ y\\/o\\ woman\\ presents\\ with\\ a\\ 4\\-month\\ history\\ of\\ itchy\\ skin\\,\\ night\\ sweats\\,\\ and\\ a\\ 20\\-lb\\ unintentional\\ weight\\ loss\\.\ \(0\)\
\-\ \\â\\€\\¢\\ signs\\ \\&\\ symptoms\ \(0\)\
\-\ often\\ asymptomatic\\ \ \(1\)\
\-\ most\\ common\\ \\=\\ painless\\ lymphadenopathy\ \(0\)\
\-\ 1\\/3\\ of\\ pts\\ present\\ w\\/systemic\\ symptoms\ \(1\)\
\-\ fatigue\\,\\ generalized\\ pruritis\\,\\ \\â\\€\\œb\\â\\€\\\\ symptoms\\ \\[low\\-grade\\ fever\\,\\ night\\ sweats\\,\\ weight\\ loss\\]\ \(0\)\
\-\ mediastinal\\ masses\\ may\\ also\\ produce\\ mass\\ effects\ \(0\)\
\-\ \\â\\€\\¢\\ subtypes\ \(0\)\
\-\ nodular\\ sclerosing\ \(5\)\
\-\ mixed\\ cellularity\\ \ \(1\)\
\-\ lymphocyte\\-depleted\ \(0\)\
\-\ lymphocyte\\-rich\ \(0\)\
\-\ nodular\\ lymphocyte\\-predominant\ \(0\)\
\-\ \\â\\€\\¢\\ nodular\\ sclerosing\\ subtype\ \(0\)\
\-\ most\\ common\\ subtype\\ in\\ the\\ us\ \(0\)\
\-\ affects\\ females\\ \\>\\ males\ \(0\)\
\-\ median\\ age\\ of\\ onset\\ \\=\\ mid\\-20\\â\\€\\™s\ \(0\)\
\-\ \\â\\€\\¢\\ bimodal\\ peak\\ distribution\\ of\\ onset\\ \ \(0\)\
\-\ young\\ adults\\ \\(15\\-35\\)\\ and\\ late\\ adulthood\\ \\(\\>55\\)\ \(0\)\
\-\ associated\\ with\\ ebv\\ and\\ hiv\ \(0\)\
\-\ http\\:\\/\\/www\\.uptodate\\.com\\/contents\\/anterior\\-mediastinal\\-mass\\-lesions\ \(1\)\
\-\ http\\:\\/\\/emedicine\\.medscape\\.com\\/article\\/201886\\-overview\ \(1\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ mediastinal\\:\\ 0\\.33630440005779794\ \(0\)\
\-\ nodular\\:\\ 0\\.2211114584851722\ \(0\)\
\-\ sclerosing\\:\\ 0\\.21936336650062477\ \(0\)\
\-\ pts\\:\\ 0\\.16722633658509034\ \(0\)\
\-\ subtype\\:\\ 0\\.16365842085445254\ \(0\)\
\-\ sweats\\:\\ 0\\.14180505105367697\ \(0\)\
\-\ 20\\:\\ 0\\.13434497701262527\ \(0\)\
\-\ mass\\:\\ 0\\.13257162085240284\ \(0\)\
\-\ night\\:\\ 0\\.12471149313007716\ \(0\)\
\-\ common\\:\\ 0\\.11809719625827735\ \(0\)\
\-\ anterior\\:\\ 0\\.11627029213550702\ \(0\)\
\-\ young\\:\\ 0\\.1144743023248873\ \(0\)\
\-\ symptoms\\:\\ 0\\.11393835160947996\ \(0\)\
\-\ abvd\\:\\ 0\\.11100821969491204\ \(0\)\
\-\ dacarbazine\\:\\ 0\\.11100821969491204\ \(0\)\
\-\ itchy\\:\\ 0\\.11100821969491204\ \(0\)\
\-\ most\\:\\ 0\\.1083755619909753\ \(0\)\
\-\ http\\:\\ 0\\.1026358643961842\ \(0\)\
\-\ adriamycin\\:\\ 0\\.09763965497222085\ \(0\)\
\-\ bleomycin\\:\\ 0\\.09763965497222085\ \(0\)\
\-\ vinblastine\\:\\ 0\\.09763965497222085\ \(0\)\
\-\ weight\\:\\ 0\\.09681176968004736\ \(0\)\
\-\ bimodal\\:\\ 0\\.09413896920272878\ \(0\)\
\-\ pruritis\\:\\ 0\\.0902638356733179\ \(0\)\
\-\ cellularity\\:\\ 0\\.0902638356733179\ \(0\)\
\-\ unintentional\\:\\ 0\\.08920502972612923\ \(0\)\
\-\ onset\\:\\ 0\\.0891455020122927\ \(0\)\
\-\ doxorubicin\\:\\ 0\\.0864896868895661\ \(0\)\
\-\ ebv\\:\\ 0\\.0864896868895661\ \(0\)\
\-\ loss\\:\\ 0\\.08457919869982453\ \(0\)\
\-\ lymphoma\\:\\ 0\\.08268076127350103\ \(0\)\
\-\ subtypes\\:\\ 0\\.08182921042722627\ \(0\)\
\-\ of\\:\\ 0\\.0815041650924172\ \(0\)\
\-\ adulthood\\:\\ 0\\.08128829506418557\ \(0\)\
\-\ thymic\\:\\ 0\\.07765605566732053\ \(0\)\
\-\ thymoma\\:\\ 0\\.07583646500343805\ \(0\)\
\-\ enteric\\:\\ 0\\.07285366981809394\ \(0\)\
\-\ effects\\:\\ 0\\.07208487154035034\ \(0\)\
\-\ median\\:\\ 0\\.07183903303741927\ \(0\)\
\-\ males\\:\\ 0\\.07159806294504095\ \(0\)\
\-\ affects\\:\\ 0\\.07112998246734027\ \(0\)\
\-\ peak\\:\\ 0\\.07112998246734027\ \(0\)\
\-\ hodgkin\\:\\ 0\\.07090252552683848\ \(0\)\
\-\ females\\:\\ 0\\.06982495536311084\ \(0\)\
\-\ produce\\:\\ 0\\.06962043639738284\ \(0\)\
\-\ great\\:\\ 0\\.06864642934398424\ \(0\)\
\-\ hiv\\:\\ 0\\.06864642934398424\ \(0\)\
\-\ pericardial\\:\\ 0\\.06791973034149437\ \(0\)\
\-\ survival\\:\\ 0\\.06774463966583899\ \(0\)\
\-\ ascending\\:\\ 0\\.06757203262975021\ \(0\)\
\-\ fatigue\\:\\ 0\\.06723399444779629\ \(0\)\
\-\ bronchogenic\\:\\ 0\\.06674391780036192\ \(0\)\
\-\ generalized\\:\\ 0\\.0662728166966027\ \(0\)\
\-\ late\\:\\ 0\\.06552604302580256\ \(0\)\
\-\ germ\\:\\ 0\\.06482246025721493\ \(0\)\
\-\ adults\\:\\ 0\\.06482246025721493\ \(0\)\
\-\ standard\\:\\ 0\\.0644190445720023\ \(0\)\
\-\ painless\\:\\ 0\\.06428749094462935\ \(0\)\
\-\ prognosis\\:\\ 0\\.06108482640563212\ \(0\)\
\-\ 55\\:\\ 0\\.059662751929457254\ \(0\)\
\-\ arch\\:\\ 0\\.05888300246572093\ \(0\)\
\-\ healthy\\:\\ 0\\.05888300246572093\ \(0\)\
\-\ distribution\\:\\ 0\\.05888300246572093\ \(0\)\
\-\ mixed\\:\\ 0\\.057459076924661893\ \(0\)\
\-\ and\\:\\ 0\\.05737427624071646\ \(0\)\
\-\ 23\\:\\ 0\\.05723715116244365\ \(0\)\
\-\ good\\:\\ 0\\.05645639064041966\ \(0\)\
\-\ aorta\\:\\ 0\\.0563878350111233\ \(0\)\
\-\ lymphadenopathy\\:\\ 0\\.05611741072631233\ \(0\)\
\-\ previously\\:\\ 0\\.05572271908880111\ \(0\)\
\-\ 90\\:\\ 0\\.05546652874176271\ \(0\)\
\-\ us\\:\\ 0\\.05521562104816708\ \(0\)\
\-\ especially\\:\\ 0\\.054909091187433826\ \(0\)\
\-\ vessels\\:\\ 0\\.053865429725105114\ \(0\)\
\-\ aortic\\:\\ 0\\.053645177702902204\ \(0\)\
\-\ aneurysm\\:\\ 0\\.052853015721313845\ \(0\)\
\-\ rate\\:\\ 0\\.05260002132754775\ \(0\)\
\-\ cysts\\:\\ 0\\.05260002132754775\ \(0\)\
\-\ skin\\:\\ 0\\.05163757588263342\ \(0\)\
\-\ tumors\\:\\ 0\\.05105047984931112\ \(0\)\
\-\ signs\\:\\ 0\\.04851278384680249\ \(0\)\
\-\ asymptomatic\\:\\ 0\\.04725577352619428\ \(0\)\
\-\ masses\\:\\ 0\\.04725577352619428\ \(0\)\
\-\ fever\\:\\ 0\\.04706363387092326\ \(0\)\
\-\ surrounding\\:\\ 0\\.04629418720676607\ \(0\)\
\-\ often\\:\\ 0\\.045292680498693706\ \(0\)\
\-\ superior\\:\\ 0\\.0451289749981172\ \(0\)\
\-\ age\\:\\ 0\\.043578844370202936\ \(0\)\
\-\ with\\:\\ 0\\.040776431905819276\ \(0\)\
\-\ cell\\:\\ 0\\.03970804979324105\ \(0\)\
\-\ associated\\:\\ 0\\.03658642361648025\ \(0\)\
\-\ tissue\\:\\ 0\\.03641305992126834\ \(0\)\
\-\ woman\\:\\ 0\\.036151077961399214\ \(0\)\
\-\ present\\:\\ 0\\.035618617119656214\ \(0\)\
\-\ may\\:\\ 0\\.03493135202809068\ \(0\)\
\-\ presents\\:\\ 0\\.033391753772770406\ \(0\)\
\-\ treatment\\:\\ 0\\.033065607830794104\ \(0\)\
\-\ also\\:\\ 0\\.032650392191907136\ \(0\)\
\-\ disease\\:\\ 0\\.029137563329885277\ \(0\)\
\-\ the\\:\\ 0\\.027701246886506152\ \(0\)\
\-\ history\\:\\ 0\\.026520195626331178\ \(0\)\
\-\ year\\:\\ 0\\.021392051708353673\ \(0\)\
\-\ for\\:\\ 0\\.021038873834151487\ \(0\)\
\-\ is\\:\\ 0\\.01900951642920879\ \(0\)\
\-\ in\\:\\ 0\\.017267969442600496\ \(0\)\
